|
CN117209447A
(zh)
|
2017-07-24 |
2023-12-12 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
PE20200758A1
(es)
|
2017-08-15 |
2020-07-27 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
|
|
WO2019068772A1
(en)
|
2017-10-03 |
2019-04-11 |
Inflazome Limited |
NEW COMPOUNDS
|
|
US20210395241A1
(en)
*
|
2018-07-03 |
2021-12-23 |
Novartis Ag |
Nlrp modulators
|
|
CA3103664A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
PE20211333A1
(es)
|
2018-08-15 |
2021-07-22 |
Inflazome Ltd |
Compuestos de sulfonamidaurea novedosos
|
|
CN120531732A
(zh)
*
|
2018-11-13 |
2025-08-26 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
US12134611B2
(en)
|
2018-11-13 |
2024-11-05 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
CN113227055A
(zh)
*
|
2018-11-16 |
2021-08-06 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
EP4013762A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
|
|
JP2022545400A
(ja)
|
2019-08-16 |
2022-10-27 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
JP2023513935A
(ja)
|
2020-02-18 |
2023-04-04 |
インフレイゾーム リミテッド |
化合物
|
|
AU2021244313A1
(en)
|
2020-03-25 |
2022-11-17 |
Olatec Therapeutics Llc |
Method for treating diabetes
|
|
CA3178361A1
(en)
|
2020-06-19 |
2021-12-23 |
Emanuele Gabellieri |
Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
WO2022237781A1
(zh)
*
|
2021-05-10 |
2022-11-17 |
成都百裕制药股份有限公司 |
酰胺衍生物及其应用
|
|
US20250109126A1
(en)
|
2021-12-22 |
2025-04-03 |
Ac Immune Sa |
Dihydro-oxazol derivative compounds
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CN119998284A
(zh)
|
2022-07-28 |
2025-05-13 |
Ac免疫有限公司 |
新化合物
|
|
WO2024249539A1
(en)
|
2023-06-02 |
2024-12-05 |
Merck Sharp & Dohme Llc |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
TW202545527A
(zh)
|
2024-01-16 |
2025-12-01 |
英商諾得瑟拉公司 |
Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
CN119680348A
(zh)
*
|
2025-02-05 |
2025-03-25 |
上海惠志环保科技有限公司 |
一种应用于含高浓度二氯甲烷废气处理方法及其系统
|